TY  - JOUR
AU  - Bolsewig, Katharina
AU  - Willemse, Eline A J
AU  - Sánchez-Juan, Pascual
AU  - Rábano, Alberto
AU  - Martínez, Minerva
AU  - Doecke, James D
AU  - Bellomo, Giovanni
AU  - Vermunt, Lisa
AU  - Alcolea, Daniel
AU  - Halbgebauer, Steffen
AU  - In 't Veld, Sjors
AU  - Mattsson-Carlgren, Niklas
AU  - Veverova, Katerina
AU  - Fowler, Christopher J
AU  - Boonkamp, Lynn
AU  - Koel-Simmelink, Marleen
AU  - Hussainali, Zulaiga
AU  - Ruiters, Daimy N
AU  - Gaetani, Lorenzo
AU  - Toja, Andrea
AU  - Fortea, Juan
AU  - Pijnenburg, Yolande
AU  - Lemstra, Afina W
AU  - van der Flier, Wiesje M
AU  - Hort, Jakub
AU  - Otto, Markus
AU  - Hansson, Oskar
AU  - Parnetti, Lucilla
AU  - Masters, Colin L
AU  - Lleó, Alberto
AU  - Teunissen, Charlotte E
AU  - Del Campo Milán, Marta
TI  - Increased plasma DOPA decarboxylase levels in Lewy body disorders are driven by dopaminergic treatment.
JO  - Nature Communications
VL  - 16
IS  - 1
SN  - 2041-1723
CY  - [London]
PB  - Springer Nature
M1  - DZNE-2025-00286
SP  - 1139
PY  - 2025
AB  - DOPA Decarboxylase (DDC) has been proposed as a cerebrospinal fluid (CSF) biomarker with increased concentrations in Lewy body disorders (LBDs) and highest levels in patients receiving dopaminergic treatment. Here we evaluate plasma DDC, measured by proximity extension assay, and the effect of dopaminergic treatment in three independent LBD (with a focus on dementia with Lewy bodies (DLB) and Parkinson's disease (PD)) cohorts: an autopsy-confirmed cohort (n = 71), a large multicenter, cross-dementia cohort (n = 1498) and a longitudinal cohort with detailed treatment information (n = 66, median follow-up time[IQR] = 4[4, 4] years). Plasma DDC was not altered between different LBDs and other disease groups or controls in absence of treatment. DDC levels increased over time in PD, being significantly associated to higher dosages of dopaminergic treatment. This emphasizes the need to consider treatment effect when analyzing plasma DDC, and suggests that plasma DDC, in contrast to CSF DDC, is of limited use as a diagnostic biomarker for LBD, but could be valuable for treatment monitoring.
KW  - Humans
KW  - Lewy Body Disease: drug therapy
KW  - Lewy Body Disease: blood
KW  - Lewy Body Disease: cerebrospinal fluid
KW  - Dopa Decarboxylase: metabolism
KW  - Male
KW  - Female
KW  - Aged
KW  - Parkinson Disease: drug therapy
KW  - Parkinson Disease: blood
KW  - Parkinson Disease: cerebrospinal fluid
KW  - Biomarkers: blood
KW  - Biomarkers: cerebrospinal fluid
KW  - Aged, 80 and over
KW  - Middle Aged
KW  - Dopamine Agents: therapeutic use
KW  - Cohort Studies
KW  - Longitudinal Studies
KW  - Dopa Decarboxylase (NLM Chemicals)
KW  - Biomarkers (NLM Chemicals)
KW  - Dopamine Agents (NLM Chemicals)
LB  - PUB:(DE-HGF)16
C6  - pmid:39881147
DO  - DOI:10.1038/s41467-025-56293-z
UR  - https://pub.dzne.de/record/276323
ER  -